Matt Gamache-Asselin
Angel Investor
Matt Gamache-Asselin is a Series A investor focused on Health Care and Personal Health. Matt Gamache-Asselin
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Matt Gamache-Asselin invests in
Stages Matt Gamache-Asselin invests in
Countries Matt Gamache-Asselin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Personal Health 2 (67%)
- Legal 1 (33%)
- Medical 1 (33%)
- Software 1 (33%)
Stage
- Series A 2 (67%)
- Pre-Seed 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Blue is an AI-powered EHR purpose-built for healthspan/longevity practices that gives doctors superhuman abilities, synced seamlessly with a personal health superapp for me and you.Imagine a healthcare system that actually takes care of your health *in advance* rather than fumbling to pick up the pieces after things go wrong.We'repassionate about a future in which far more diseases are prevented than treated, and it's effortless to improve your day-to-day quality of life, in both well-being and performance.Science >> Snake Oil | Pre-Seed / Jul 04, 2024 | ||
| Getlabs is the leading platform for at-home diagnostics.Healthcare organizations use Getlabs to send mobile phlebotomists to patients’ homes and collect labs, vitals, and advanced diagnostics. By leveraging Getlabs, partners can improve patient adherence and close gaps in care with same-day, nationwide availability.Our team has raised $50M fromstrategic investors including the two largest diagnostic laboratories in the United States, Labcorp and Quest. Getlabs’ mission is to save lives by expanding access to diagnostics for everyone. | $20M / Series A / Feb 03, 2022 | ||
| Atrium builds products and services to help automate legal workflows, innovate new processes within law firms, and help firms identify and attract new clients. Its technology provides a better experience for legal clients than they previously thought possible, increasing communication and speed of service.The company collaborates withforward-thinking lawyers to help determine the direction and decisions for these products. | $10.5M / Series A / Jun 15, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Matt Gamache-Asselin invest in?
Matt Gamache-Asselin invests primarily in Health Care, Personal Health and Legal startups, most often at Series A and Pre-Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Matt Gamache-Asselin?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Matt Gamache-Asselin last invest?
The most recent investment recorded for Matt Gamache-Asselin closed in Jul 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
